NO20001407L - Vitronectin-reseptor-antagonister - Google Patents
Vitronectin-reseptor-antagonisterInfo
- Publication number
- NO20001407L NO20001407L NO20001407A NO20001407A NO20001407L NO 20001407 L NO20001407 L NO 20001407L NO 20001407 A NO20001407 A NO 20001407A NO 20001407 A NO20001407 A NO 20001407A NO 20001407 L NO20001407 L NO 20001407L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- receptor antagonists
- vitronectin receptor
- halogen
- vitronectin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5934297P | 1997-09-19 | 1997-09-19 | |
US6343897P | 1997-10-29 | 1997-10-29 | |
PCT/US1998/019466 WO1999015508A1 (en) | 1997-09-19 | 1998-09-18 | Vitronectin receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20001407L true NO20001407L (no) | 2000-03-17 |
NO20001407D0 NO20001407D0 (no) | 2000-03-17 |
Family
ID=26738652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20001407A NO20001407D0 (no) | 1997-09-19 | 2000-03-17 | Vitronectin-reseptor-antagonister |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1025090A4 (zh) |
JP (1) | JP2001517658A (zh) |
KR (1) | KR20010024141A (zh) |
CN (1) | CN1278250A (zh) |
AP (1) | AP2000001766A0 (zh) |
AR (1) | AR015446A1 (zh) |
AU (1) | AU738433B2 (zh) |
BG (1) | BG104314A (zh) |
BR (1) | BR9812340A (zh) |
CA (1) | CA2303487A1 (zh) |
CO (1) | CO5011087A1 (zh) |
DZ (1) | DZ2609A1 (zh) |
EA (1) | EA200000336A1 (zh) |
HU (1) | HUP0003641A3 (zh) |
ID (1) | ID24162A (zh) |
IL (1) | IL135028A0 (zh) |
MA (1) | MA26547A1 (zh) |
NO (1) | NO20001407D0 (zh) |
NZ (1) | NZ503389A (zh) |
OA (1) | OA11341A (zh) |
PE (1) | PE122699A1 (zh) |
PL (1) | PL339381A1 (zh) |
SK (1) | SK4082000A3 (zh) |
TR (1) | TR200000721T2 (zh) |
TW (1) | TW513303B (zh) |
WO (1) | WO1999015508A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
AU747503B2 (en) | 1999-02-03 | 2002-05-16 | Merck & Co., Inc. | Benzazepine derivatives as alpha-V integrin receptor antagonists |
DE19936780A1 (de) | 1999-08-09 | 2001-02-15 | Basf Ag | Neue Antagonisten von Integrinrezeptoren |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2001096310A1 (en) * | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
DE60118025T2 (de) * | 2000-10-24 | 2006-11-23 | Merck & Co., Inc. | Dibenzoxazepin-alpha-v-integrin-rezeptorantagonist |
AU2002316855B2 (en) | 2001-04-24 | 2008-03-13 | Merck Patent Gmbh | Combination therapy using anti-angiogenic agents and TNFalpha |
GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
ES2425396T3 (es) | 2006-01-18 | 2013-10-15 | Merck Patent Gmbh | Terapia específica usando ligandos de integrinas para el tratamiento del cáncer |
DK2101805T3 (da) | 2007-01-18 | 2013-01-21 | Merck Patent Gmbh | Integrinligander til anvendelse i behandling af cancer |
JP2012528079A (ja) | 2009-05-25 | 2012-11-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するためのインテグリンリガンドの連続投与 |
US10328082B2 (en) | 2014-05-30 | 2019-06-25 | Pfizer Inc. | Methods of use and combinations |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH450398A (de) * | 1964-02-18 | 1968-01-31 | Hoffmann La Roche | Verfahren zur Herstellung von Dibenzocycloheptatrienverbindungen |
US3335148A (en) * | 1966-02-17 | 1967-08-08 | Lilly Co Eli | 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof |
US5698551A (en) * | 1995-04-07 | 1997-12-16 | Novo Nordisk A/S | Heterocyclic compounds |
DE69627899T2 (de) * | 1995-06-29 | 2004-05-19 | Smithkline Beecham Corp. | Integrin-rezeptor-antagonisten |
US5659033A (en) * | 1995-09-13 | 1997-08-19 | Neurogen Corporation | N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands |
JP2001501951A (ja) * | 1996-10-07 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | 骨形成刺激方法 |
CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
-
1998
- 1998-09-16 PE PE1998000881A patent/PE122699A1/es not_active Application Discontinuation
- 1998-09-16 AR ARP980104604A patent/AR015446A1/es not_active Application Discontinuation
- 1998-09-16 DZ DZ980219A patent/DZ2609A1/xx active
- 1998-09-18 ID IDW20000468A patent/ID24162A/id unknown
- 1998-09-18 AU AU93972/98A patent/AU738433B2/en not_active Ceased
- 1998-09-18 JP JP2000512816A patent/JP2001517658A/ja not_active Withdrawn
- 1998-09-18 KR KR1020007002901A patent/KR20010024141A/ko not_active Application Discontinuation
- 1998-09-18 IL IL13502898A patent/IL135028A0/xx unknown
- 1998-09-18 MA MA25266A patent/MA26547A1/fr unknown
- 1998-09-18 NZ NZ503389A patent/NZ503389A/en not_active IP Right Cessation
- 1998-09-18 CN CN98810811A patent/CN1278250A/zh active Pending
- 1998-09-18 AP APAP/P/2000/001766A patent/AP2000001766A0/en unknown
- 1998-09-18 WO PCT/US1998/019466 patent/WO1999015508A1/en not_active Application Discontinuation
- 1998-09-18 EA EA200000336A patent/EA200000336A1/ru unknown
- 1998-09-18 SK SK408-2000A patent/SK4082000A3/sk unknown
- 1998-09-18 HU HU0003641A patent/HUP0003641A3/hu unknown
- 1998-09-18 TR TR2000/00721T patent/TR200000721T2/xx unknown
- 1998-09-18 PL PL98339381A patent/PL339381A1/xx unknown
- 1998-09-18 EP EP98947116A patent/EP1025090A4/en not_active Withdrawn
- 1998-09-18 CA CA002303487A patent/CA2303487A1/en not_active Abandoned
- 1998-09-18 CO CO98053986A patent/CO5011087A1/es unknown
- 1998-09-18 BR BR9812340-8A patent/BR9812340A/pt not_active Application Discontinuation
- 1998-09-23 TW TW087115535A patent/TW513303B/zh not_active IP Right Cessation
-
2000
- 2000-03-16 OA OA1200000079A patent/OA11341A/en unknown
- 2000-03-17 NO NO20001407A patent/NO20001407D0/no not_active Application Discontinuation
- 2000-04-07 BG BG104314A patent/BG104314A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EA200000336A1 (ru) | 2000-10-30 |
TW513303B (en) | 2002-12-11 |
CO5011087A1 (es) | 2001-02-28 |
PE122699A1 (es) | 2000-02-12 |
CN1278250A (zh) | 2000-12-27 |
WO1999015508A1 (en) | 1999-04-01 |
KR20010024141A (ko) | 2001-03-26 |
NO20001407D0 (no) | 2000-03-17 |
OA11341A (en) | 2003-12-10 |
CA2303487A1 (en) | 1999-04-01 |
ID24162A (id) | 2000-07-13 |
PL339381A1 (en) | 2000-12-18 |
IL135028A0 (en) | 2001-05-20 |
DZ2609A1 (fr) | 2003-03-01 |
AR015446A1 (es) | 2001-05-02 |
AU738433B2 (en) | 2001-09-20 |
AP2000001766A0 (en) | 1998-09-18 |
AU9397298A (en) | 1999-04-12 |
MA26547A1 (fr) | 2004-12-20 |
HUP0003641A2 (en) | 2001-03-28 |
EP1025090A1 (en) | 2000-08-09 |
NZ503389A (en) | 2002-03-28 |
HUP0003641A3 (en) | 2002-10-28 |
TR200000721T2 (tr) | 2000-11-21 |
BR9812340A (pt) | 2001-12-18 |
EP1025090A4 (en) | 2000-11-08 |
SK4082000A3 (en) | 2000-09-12 |
JP2001517658A (ja) | 2001-10-09 |
BG104314A (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20001407L (no) | Vitronectin-reseptor-antagonister | |
NO983002L (no) | Vitronectin-reseptor-antagonister | |
ATE249213T1 (de) | Pentafluorobenzensulfonamiden und analoge | |
PT1222195E (pt) | Novos compostos de tiazolo(4,5-d)pirimidina | |
ATE168685T1 (de) | Aminoheterocyclische derivate als antithrombotische oder antikoagulierende mittel | |
ATE139233T1 (de) | Annelierte thiophen-derivate, ihre herstellung und verwendung | |
DE69011318D1 (de) | Diazinderivate als Angiotensin II Rezeptor Antagonisten. | |
NO20001514L (no) | Vitronectin-reseptor-antagonist | |
NO20001515L (no) | Vitronektin reseptor-antagonist | |
NO961000L (no) | Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
DK0474580T3 (da) | Anvendelse af 1-(3-dimethylamino)propyl)-1-phenylphthalener til behandling af cerebrovaskulære sygdomme | |
BR8800473A (pt) | Processos para preparacao de compostos,e composicoes | |
NO975094L (no) | Vinylpyrrolidoncefalosporinderivater | |
GR920100570A (el) | Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους. | |
NO982927L (no) | Biologisk aktive benzotiazolon etanaminer | |
GR76083B (zh) | ||
DE59307133D1 (de) | Gestagen wirksame 19,11-überbrückte 4-estrene | |
DK0885004T3 (da) | Anvendelse af 4-phenyl-3,6-dihydro-2H-pyridyl-derivater som NMDA-receptor-undertypeblokkere | |
FI843155A0 (fi) | Framstaellning av indolinderivat och deras terapeutiska tillaempning. | |
BR9912885A (pt) | Derivado de 3-azabiciclo-[3.2.0]- heptano n-substituìdo | |
DK0462468T3 (da) | 9-amino-2-phenylbicyclo(3.3.1)nonaner og 9-amino-2-phenylbicyclo(3.3.1)non-2-ener og terapeutiske midler indeholdende disse | |
CO4770971A1 (es) | Compuestos quimicos | |
TR199801735A2 (xx) | 2-(arilfenil)amino-imidazolin türevleri. | |
TH13127EX (th) | ซับสทิทิวเทดพิราโซลิลพิราโซลชนิดใหม่, กรรมวิธีสำหรับการเตรียมของสารพวกนี้และอินเทอร์มิเดียทต่าง ๆ เช่นเดียวกัน, และการใช้สารพวกนี้เป็นสารฆ่าวัชพืช |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |